Tan Li
Founder at SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Net worth: 584 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Allan Bradley | M | 64 |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 14 years |
| Li Li | M | 60 |
Sichuan University
Shenzhen Duopule Industrial Development Co., Ltd.
 Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.
Shenzhen Techdow Pharmaceutical Co., Ltd.
| 31 years |
| Yu Shan | M | 64 |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | 26 years |
| Timothy James Rink | M | 78 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Ji Lan Su | F | 45 | 20 years | |
| Ming Yi | M | 47 | 1 years | |
| Feng Qi Qian | M | 39 | 3 years | |
| Chu An Lü | M | 54 | 5 years | |
| Erwin Boos | M | 46 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Simone Song | F | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Christian Itin | M | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Timothy Nigel Carl Wells | M | 62 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Alan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | - |
| Peng Huang | M | 75 | 1 years | |
| Hai Jun Tang | F | 46 | 23 years | |
| Ze Hui Zheng | M | 54 | 10 years | |
| Jasper Clube | M | 56 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Wen Xuan Zhang | M | 35 | - | |
| Nigel Clark | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Glenn Alfons Friedrich | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Volker Germaschewski | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Douglas Fearon | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Paul Kellam | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 years |
| Juan Chen | F | 49 | 1 years | |
| Ping Zhang | M | 59 | 1 years | |
| Tao Han | F | - | - | |
| Ming Jie Wu | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bin Zhang | M | 47 | 6 years | |
| Yong Li | M | 55 |
Sichuan University
| 6 years |
| Dong Xie | M | 59 | 6 years | |
| Hai Meng Zhou | M | 78 | 7 years | |
| Hai Hua Bu | M | 48 | 15 years | |
| Ying Jiang | M | 58 |
Sichuan University
| 6 years |
| Jun Fa Chen | M | 59 | 6 years | |
| Rong Qing Zhang | M | 67 | - | |
| Xin Qian | F | 68 | 13 years | |
| Zhao Hui Wang | M | 46 | 6 years | |
| Xian Qing Xiang | M | 49 | 1 years | |
| Bin Xu | M | 55 | - | |
| Jirui Yang | M | 69 |
Sichuan University
| 6 years |
| Yuan Wei Chen | M | 61 |
Sichuan University
| 6 years |
| Jie Weng | M | 61 |
Sichuan University
| 9 years |
| Xuan Sun | M | 48 | 1 years | |
| Yuan Tu Ye | M | 60 |
Sichuan University
| 4 years |
| Pei Yao | M | 60 |
Sichuan University
| 4 years |
| De Cheng Wang | M | 59 |
Sichuan University
| 4 years |
| Chen Guang Yan | M | 57 | - | |
| Yun Kong | F | 51 | 10 years | |
| Lan Wang | M | 54 |
Sichuan University
| 4 years |
| Chun Rong Zhu | M | 55 |
Sichuan University
| 4 years |
| Quan Yang | M | 59 |
Sichuan University
| 4 years |
| Shou Yin Qi | M | 73 |
Sichuan University
| 1 years |
| Zi Hou Yan | M | 60 |
Sichuan University
| 4 years |
| Yong Zhuo | M | 58 |
Sichuan University
| 4 years |
| Lan Liu | F | 57 |
Sichuan University
| 4 years |
| Mao Yin Wu | M | 57 |
Sichuan University
| 4 years |
| Ying Lin Han | M | - |
Sichuan University
| 4 years |
| Hong Yin | M | 62 |
Sichuan University
| 2 years |
| Sheng Hua Wei | M | 58 |
Sichuan University
| 4 years |
| Shawn Lu | M | 56 | 1 years | |
| Yan Ming Wang | M | 67 |
Sichuan University
| 3 years |
| Wen Tan | M | 55 |
Sichuan University
| 4 years |
| Ming Dai | M | 55 |
Sichuan University
| 4 years |
| Xuan Tan | F | 42 | 1 years | |
| Zhi Cheng Wang | M | 59 |
Sichuan University
| 4 years |
| Jun Hua Wang | M | 59 |
Sichuan University
| 4 years |
| Liang Cai Liu | M | 72 |
Sichuan University
| 4 years |
| Shudong Huang | M | - |
Sichuan University
| 4 years |
| Changjiu Yu | M | 67 |
Sichuan University
| 4 years |
| Peng Wang | M | 65 |
Sichuan University
| 1 years |
| Gang Yu | M | 58 |
Sichuan University
| 4 years |
| Ming Yin Xu | F | 49 | 7 years | |
| WenBo Xie | M | - |
Sichuan University
| 4 years |
| Yonghong Hu | M | - |
Sichuan University
| 4 years |
| Nengyi Sun | M | 75 |
Sichuan University
| 4 years |
| Xian Ping Lu | M | 61 |
Sichuan University
| 4 years |
| Shu Mei Zhao | F | 61 |
Sichuan University
| 4 years |
| Ji Hui Yi | M | - |
Sichuan University
| 4 years |
| Ying Jie Deng | M | 60 |
Sichuan University
| 1 years |
| Chong Zou | M | 54 |
Sichuan University
| 4 years |
| Gang Qiang Liu | M | 50 |
Sichuan University
| 4 years |
| Ting Jun Yuan | F | - |
Sichuan University
| 4 years |
| Xing Qiang Yang | M | 57 |
Sichuan University
| 4 years |
| En Chen Liu | M | 61 |
Sichuan University
| 4 years |
| Yong Hong Yuan | M | 57 |
Sichuan University
| 4 years |
| Jing Zhang | M | 69 |
Sichuan University
| 4 years |
| Mei Wen Zhang | M | 60 |
Sichuan University
| 4 years |
| Yan Dai | M | 59 |
Sichuan University
| 4 years |
| Zhi Jian Wu | M | 60 |
Sichuan University
| 4 years |
| Huaili Zheng | M | 66 |
Sichuan University
| 1 years |
| Bing Shang | M | 56 |
Sichuan University
| 5 years |
| Ping Zhao | M | 62 |
Sichuan University
| 4 years |
| Yue Qiang Zong | M | 59 |
Sichuan University
| 4 years |
| Qing Ke Ma | M | 61 |
Sichuan University
| 4 years |
| Hong Wei Zhu | M | 60 |
Sichuan University
| 4 years |
| Chun Ming Luo | M | 58 |
Sichuan University
| 4 years |
| Zi Gui Xu | M | 59 |
Sichuan University
| 4 years |
| Jun Xiang Hu | M | 60 |
Sichuan University
| 4 years |
| Ming Chun Wang | M | 64 |
Sichuan University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| China | 86 | 86.00% |
| United Kingdom | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Tan Li
- Personal Network
